Generated by AI
GeneDx Holdings Corp. Class A Common Stock is the equity security of GeneDx Holdings Corp., a genomics company focused on genetic testing and clinical diagnostics. GeneDx provides pediatric and rare disease testing centered on whole exome and whole genome sequencing, along with data and information services that support more precise diagnosis and care decisions. The company also offers AI-enabled tools for sequencing analysis, interpretation, and clinical reporting across rare disease, hereditary risk, and cancer testing. Its services are used by clinicians, hospitals, and healthcare organizations that rely on genomic information to guide patient evaluation and treatment. GeneDx Holdings Corp. plays a specialized role in the healthcare market by combining laboratory testing, bioinformatics, and clinical expertise to deliver actionable genetic insights for complex medical cases.
WebsiteNorth Tower
Stamford, CT, 06902
United States
The latest articles about WGS.
GeneDx Holdings (NasdaqGS:WGS) reported new research showing exome and genome sequencing informed clinical management in over 60% of tested patients. The real-world analysis covered more than 300,000 individuals who received GeneDx genomic testing across a broad clinical setting. GeneDx plans to present the findings at the NSGC 2026 Annual Conference, highlighting the clinical impact of its sequencing platform. The large real-world study on actionable exome and genome results is only one...
Summary of Nov 17's posts. Generated by AI.
Summary of May 6's posts. Generated by AI.
Summary of Feb 23's posts. Generated by AI.
Summary of Mar 6's posts. Generated by AI.
Investors talking about WGS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.